You are logged on as Guest.
RegisterLoginShopping cart (Empty)
 United States
Change country
Home
Products & Services
New Products
Literature
Support
Contact Us
About Us

LAG-3 (human), mAb (17B4) (ATTO 647N conjugate)

 
ALX-804-806TS-T100 100 tests ATTO 647N 452.00 USD
 

Product Specification

Alternative Name:Lymphocyte activation gene-3, FDC protein, CD223
 
Concentration:1mg/ml
 
Purity Detail:Purified from concentrated hybridoma tissue culture supernatant by Protein A Sepharose™ CL-4B Flow Fast Column.
 
Purity:≥95% (SDS-PAGE)
 
Formulation:Liquid. In PBS containing 0.02% sodium azide.
 
Clone:17B4
 
Isotype:Mouse IgG1
 
Immunogen:Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
 
Source/Host:From mouse.
 
Specificity:Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of human LAG-3.
 
Application:Flow Cytometry (1:100)
Immunocytochemistry
 
Short Term Storage:+4°C
 
Long Term Storage:+4°C
 
Use/Stability:Stable for at least 6 months after receipt when stored as recommended.
 
Handling:Do not freeze. Protect from light.
 
Background / Technical Information:1 test means: 1µl of MAb is used to stain 500’000 cells in a sample volume of 50µl.

ATTO-fluorescent antibodies show increased photostability, outstanding brightness and intense signals. ATTO dyes are thermally stable, resistant to environmental changes and show no significant isomerization. ATTO 647N shows red fluorescence (λabs (max): 645nm, λem (max): 669nm, εmax: 120’000).

SEPHAROSE is a trademark of GE Healthcare companies.
 
804-806ts
Figure: Detection of endogenous human LAG-3 by FACS analysis using LAG-3 (human), mAb (17B4) (ATTO 647) (Prod. No. ALX-804-806TS)Method: Human PBMC were stimulated (B) or not (A) with 1µg/ml of superantigen SEB. After 2 days PBMC were stained with 10µg/ml (1µg/0.5x106 cells) of LAG-3 (human), mAb (17B4) (ATTO 647) (Prod. No. ALX-804-806TS) and analyzed by flow cytometry.
Please mouse over
804-806ts

Product Literature References

Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation: C. Casati, et al.; J. Immunol. 180, 3782 (2008), Abstract;
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett. 235, 147 (2006), Abstract;
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway: E.D. Carlo, et al.; J. Pathol. 205, 82 (2005), Abstract;
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells: L. Macon-Lemaitre and F. Triebel; Immunology 115, 170 (2005), Abstract;
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts: C.E. Demeure, et al.; Eur. J. Cancer 37, 1709 (2001), Abstract;
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling: S. Hannier, et al.; J. Immunol. 161, 4058 (1998), Abstract; Full Text
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS 94, 5744 (1997), Abstract; Full Text
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics 39, 213 (1994), Abstract;
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens: E. Baixeras, et al.; J. Exp. Med. 176, 327 (1992), Abstract; Full Text
another CS2 website
©2010 Enzo Life Sciences, Inc.,